参考文献:1.T. McGovern and D. Jacobson-Kram, Trends Anal. Chem., 25(8), 790 – 795 (2006).CrossRef 2.K. L. Dearfield, M. C. Cimino, N. E. McCarroll, et al., Mutat. Res., Genet. Toxicol. Environ. Mutagen., 521, 121 – 135 (2002).CrossRef 3.R. Wear and C. Sharma, Int. J. Toxicol. Pharmacol. Res., 5(1), 33 – 41 (2013). 4.A. D. Durnev and A. S. Lapitskaya, Ekol. Genet., X(3), 41 – 52 (2012). 5. Russian Federation State Pharmacopoeia, XIIth Ed., Moscow (2007). 6. European Pharmacopoeia, 7th Ed., Suppl. 8.2; URL: http://online6.edqm.eu/ep802/ . 7. United States Pharmacopeia, 38th Ed.; URL: http://www.uspnf.com/uspnf/ . 8.E. L. Kovaleva, Standardization of Drug Substances and Drugs in Tablet Dosage Form [in Russian], Grif i K, Moscow (2012), p. 66. 9. Guideline for Elemental Impurities Q3D ICH Harmonised Guideline; URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3D/ Q3D_Step_4.pdf 10.R. W. Kashyap, B. Mitali, S. S. Rao, et al., Pharm. Technol., 36(3), 58 – 72 (2012). 11. Impurities in New Drug Substances Q3A(R2) ICH Harmonized Tripartite Guideline; URL: http://www.ich.org/fileadmin/Public_Web Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2_Guideline.pdf 12. Impurities in New Drug Products Q3B(R2) ICH Harmonised Tripartite Guideline; URL: http://www.ich.org/fileadmin/Public_Web Site/ICH_Products/Guidelines/Quality/Q3B_R2/ Step4/Q3B_R2_Guideline.pdf 13. Guideline on the Limits of Genotoxic Impurities (EMEA/CHMP/QWP/251344/2006); URL: http://www.ema . europa.eu/docs/en_GB/document library/Scientific_guideline/2009/09/WC500002903.pdf 14. Impurities: Guideline for Residual Solvents, Q3C(R5) ICHHarmonised Tripartite Guideline; URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf 15.R. Kroes, A. G. Renwick, M. Cheeseman, et al., Food Chem. Toxicol., 42(1), 65 – 83 (2004).CrossRef PubMed 16.L. Muller, R. J. Mauthe, C. M. Riley, et al., Regul. Toxicol. Pharmacol., 44(3), 198 – 211 (2006).CrossRef PubMed 17.Press Release. European Medicines Agency, EMEA/ 275367/200; URL: http://www.ema.europa.eu/docs/en GB/document_library/Press_release/2009/11/WC500014204.pdf 18.D. Polyakova, Apteka.ua online, 699(28) (2009); URL: http://www.apteka.ua/article/9065 19. http://www.pharmvestnik.ru/publs/lenta/novosti-kompanij/307 2.html#.VUyfm2zk_7U 20. Draft Guidance for Industry, Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches (CPMP/QWP/159/96 Cor.); URL: http://www.fda.gov/downloads/drugs/guidancecompliance regulatoryinformation/guidances/ucm079235.pdf [http://www.fda.gov/ohrms/dockets/98fr/fda-2008-d-0629-gdl.pdf ] 21.A. V. B. Reddy, J. Jaafar, K. Umar, et al., J. Sep. Sci., 38(5), 764 – 779 (2015).CrossRef PubMed 22. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, M7 ICH Harmonised Tripartite Guideline; URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH Products/Guidelines/Multidisciplinary/M7/M7_Step 4.pdf (accession date: Aug. 25, 2014). 23.S. V. Moiseev, V. I. Krylov, T. V. Masterkova, et al., Vedomosti NTsESMP, No. 1, 15 – 19 (2014). 24.A. A. Illarionov, L. N. Grushevskaya, L. M. Gaevaya, et al. Khim.-farm. Zh., 48(6), 48 – 53 (2014); Pharm. Chem. J., 48(6), 408 – 413 (2014). 25.D. Paul and K. Paul, World J. Pharm. Pharm. Sci., 4(2), 1124 – 1153 (2015). 26. Pharmeuropa, 26.2, 7 – 9 (2014). 27. Pharmeuropa, 26.3, 206 – 207 (2014). 28. http://grls.rosminzdrav.ru/grls.aspx 29. http://www.rosminzdrav.ru/ministry/61/11/materialy-po-deyatelnosti-deparatamenta/stranitsa-856/spisok-obschih-farmakopeynyh-statey
作者单位:O. A. Matveeva (1) E. L. Kovaleva (1)
1. Scientific Center for Expertise of Medical Products, Ministry of Public Health of the Russian Federation, 8 Petrovskii Blvd., Moscow, 127051, Russia
刊物类别:Chemistry and Materials Science
刊物主题:Pharmacy Pharmacology and Toxicology Organic Chemistry Russian Library of Science